These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

571 related articles for article (PubMed ID: 33785883)

  • 1. Antibody responses to SARS-CoV-2 infection are attenuated in infliximab-treated patients with IBD.
    Ray K
    Nat Rev Gastroenterol Hepatol; 2021 May; 18(5):286. PubMed ID: 33785883
    [No Abstract]   [Full Text] [Related]  

  • 2. Anti-SARS-CoV-2 antibody responses are attenuated in patients with IBD treated with infliximab.
    Kennedy NA; Goodhand JR; Bewshea C; Nice R; Chee D; Lin S; Chanchlani N; Butterworth J; Cooney R; Croft NM; Hart AL; Irving PM; Kok KB; Lamb CA; Limdi JK; Macdonald J; McGovern DP; Mehta SJ; Murray CD; Patel KV; Pollok RC; Raine T; Russell RK; Selinger CP; Smith PJ; Bowden J; McDonald TJ; Lees CW; Sebastian S; Powell N; Ahmad T;
    Gut; 2021 May; 70(5):865-875. PubMed ID: 33753421
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Infliximab for severe ulcerative colitis and subsequent SARS-CoV-2 pneumonia: a stone for two birds.
    Bezzio C; Manes G; Bini F; Pellegrini L; Saibeni S
    Gut; 2021 Mar; 70(3):623-624. PubMed ID: 32554621
    [No Abstract]   [Full Text] [Related]  

  • 4. Switch to subcutaneous infliximab during the SARS-CoV-2 pandemic: preliminary results.
    Argüelles-Arias F; Fernández Álvarez P; Castro Laria L; Maldonado Pérez B; Belvis Jiménez M; Merino-Bohórquez V; Caunedo Álvarez Á; Calleja Hernández MÁ
    Rev Esp Enferm Dig; 2022 Feb; 114(2):118-119. PubMed ID: 34517718
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Combination therapy of infliximab and thiopurines, but not monotherapy with infliximab or vedolizumab, is associated with attenuated IgA and neutralisation responses to SARS-CoV-2 in inflammatory bowel disease.
    Wellens J; Edmans M; Obolski U; McGregor CG; Simmonds P; Turner M; Jarvis L; Skelly D; Dunachie S; Barnes E; Eyre DW; Colombel JF; Wong SY; Klenerman P; Lindsay JO; Satsangi J; Thompson CP
    Gut; 2022 Sep; 71(9):1919-1922. PubMed ID: 34911744
    [No Abstract]   [Full Text] [Related]  

  • 6. Seroconversion of Immunoglobulins to SARS-CoV2 in Patients With Inflammatory Bowel Disease Patients Treated by Biologics.
    Fumery M; Matias C; Brochot E
    J Crohns Colitis; 2020 Dec; 14(12):1792-1793. PubMed ID: 32697842
    [No Abstract]   [Full Text] [Related]  

  • 7. Impact of Anti-Tumor Necrosis Factor and Thiopurine Medications on the Development of COVID-19 in Patients With Inflammatory Bowel Disease: A Nationwide Veterans Administration Cohort Study.
    Khan N; Patel D; Xie D; Lewis J; Trivedi C; Yang YX
    Gastroenterology; 2020 Oct; 159(4):1545-1546.e1. PubMed ID: 32479823
    [No Abstract]   [Full Text] [Related]  

  • 8. Anti-SARS-CoV-2 Antibody Responses in Patients With IBD Treated With Biologics: Are We Finding CLARITY?
    Chapman TP; Revés J; Torres J; Satsangi J
    Gastroenterology; 2021 Dec; 161(6):2057-2059. PubMed ID: 34529994
    [No Abstract]   [Full Text] [Related]  

  • 9. Maintenance therapy with infliximab or vedolizumab in IBD is not associated with increased SARS-CoV-2 seroprevalence: UK experience in the 2020 pandemic.
    McGregor CG; Adams A; Sadler R; Arancibia-Cárcamo CV; Palmer R; Ambrose T; Brain O; Walsh A; Klenerman P; Travis SP; Croft NM; Lindsay JO; Satsangi J
    Gut; 2021 Dec; 70(12):2398-2400. PubMed ID: 33579788
    [No Abstract]   [Full Text] [Related]  

  • 10. Short article: The effect of implementation of a treatment algorithm for infliximab on remission rates and drug costs in inflammatory bowel disease patients.
    Taks M; Pijls PA; Derijks LJ; Ten Broeke R; Grouls RJ; Curvers J; Gilissen LP
    Eur J Gastroenterol Hepatol; 2017 Feb; 29(2):169-173. PubMed ID: 27749780
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Biosimilar Infliximab in Inflammatory Bowel Disease: Outcomes of a Managed Switching Programme.
    Razanskaite V; Bettey M; Downey L; Wright J; Callaghan J; Rush M; Whiteoak S; Ker S; Perry K; Underhill C; Efrem E; Ahmed I; Cummings F
    J Crohns Colitis; 2017 Jun; 11(6):690-696. PubMed ID: 28130330
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Oxidative stress and thromboxane-dependent platelet activation in inflammatory bowel disease: effects of anti-TNF-α treatment.
    Di Sabatino A; Santilli F; Guerci M; Simeone P; Ardizzone S; Massari A; Giuffrida P; Tripaldi R; Malara A; Liani R; Gurini E; Aronico N; Balduini A; Corazza GR; Davì G
    Thromb Haemost; 2016 Aug; 116(3):486-95. PubMed ID: 27305860
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Sex Disparities and Neutralizing-Antibody Durability to SARS-CoV-2 Infection in Convalescent Individuals.
    Markmann AJ; Giallourou N; Bhowmik DR; Hou YJ; Lerner A; Martinez DR; Premkumar L; Root H; van Duin D; Napravnik S; Graham SD; Guerra Q; Raut R; Petropoulos CJ; Wrin T; Cornaby C; Schmitz J; Kuruc J; Weiss S; Park Y; Baric R; de Silva AM; Margolis DM; Bartelt LA
    mSphere; 2021 Aug; 6(4):e0027521. PubMed ID: 34431693
    [TBL] [Abstract][Full Text] [Related]  

  • 14. COVID-19 and IBD drugs: should we change anything at the moment?
    Lees CW; Irving PM; Beaugerie L
    Gut; 2021 Apr; 70(4):632-634. PubMed ID: 33214164
    [No Abstract]   [Full Text] [Related]  

  • 15. Antibody Response against SARS-CoV-2 and Seasonal Coronaviruses in Nonhospitalized COVID-19 Patients.
    Ruetalo N; Businger R; Althaus K; Fink S; Ruoff F; Pogoda M; Iftner A; Ganzenmüller T; Hamprecht K; Flehmig B; Bakchoul T; Templin MF; Schindler M
    mSphere; 2021 Feb; 6(1):. PubMed ID: 33627511
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Antibody response to SARS-CoV-2 vaccination, previous SARS-CoV-2 infection, and change to single-dose vaccination.
    Mungmunpuntipantip R; Wiwanitkit V
    J Med Virol; 2021 Dec; 93(12):6474. PubMed ID: 34374991
    [No Abstract]   [Full Text] [Related]  

  • 17. COVID-19 in IBD: The experience of a single tertiary IBD center.
    Rizzello F; Calabrese C; Salice M; Calandrini L; Privitera H; Melotti L; Peruzzi G; Dussias N; Belluzzi A; Scaioli E; Decorato A; Siniscalchi A; Filippone E; Laureti S; Rottoli M; Poggioli G; Gionchetti P
    Dig Liver Dis; 2021 Mar; 53(3):271-276. PubMed ID: 33451910
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Antibody formation against SARS-CoV-2 in imatinib-treated COVID-19 patients.
    Morales-Ortega A; Farfán-Sedano AI; Izquierdo-Martínez A; Llarena-Barroso C; Jaenes-Barrios B; Mesa-Plaza N; Toledano-Macías M; Soria Fernández-Llamazares G; Molina-Esteban L; García de Tena J; Prieto-Menchero S; Gonzalo-Pascua S; San Martín-López JV; Bernal-Bello D
    J Infect; 2022 Feb; 84(2):248-288. PubMed ID: 34437930
    [No Abstract]   [Full Text] [Related]  

  • 19. T Cell Response After SARS-CoV-2 Vaccination in Immunocompromised Patients with Inflammatory Bowel Disease.
    Reuken PA; Andreas N; Grunert PC; Glöckner S; Kamradt T; Stallmach A
    J Crohns Colitis; 2022 Feb; 16(2):251-258. PubMed ID: 34379729
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Attenuated anti-SARS-CoV-2 antibody response to vaccination in patients with rheumatic diseases.
    Manolache NG; Ursachi V; Scohy A; Desmet C; Yombi JC; Nzeusseu Toukap A; Stoenoiu MS
    J Infect; 2022 Feb; 84(2):e22-e23. PubMed ID: 34920024
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 29.